Patenting monoclonal antibodies in India : evolving law and practice
Language: English Publication details: 2021ISBN:- 9781911432463
SNIPER Book Chapter
As efforts continue to find an effective treatment and vaccine for covid-19, monoclonal antibodies have been at the forefront of research with reportedly more than 100 covid-19 antibody treatments at various stages of clinical trials - some designed solely to deal with secondary effects of SARS-CoV-2 (eg, inflammation), while others are designed to destroy the vims itself. Monoclonal antibodies have dominated biotechnology research in the past 25 years, and it is interesting to see how Indian patent law has responded to their protection -- legal framework -- naturally occurring? -- broad antibody claims -- sufficiency of disclosure -- demonstrating inventive merits -- overcoming Section 3(d) of the Patents Act
Creative Commons Attribution 4.0 International (CC BY 4.0)
Item type | Current library | Call number | Status | Date due | Barcode | Item holds | |
---|---|---|---|---|---|---|---|
SNIPER | IP Australia Library SNIPER Articles | 2022/00383 (Browse shelf(Opens below)) | Available | 200803108 |
There are no comments on this title.